Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07013591 · ClinicalTrials.gov registry record · Phase 2
Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT07013591 is a Phase 2 study that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 90 participants.
The verdict
NCT07013591, a Phase 2 study, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.
Interventions
- OTHER Placebo
- DRUG MIB-626
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-06-10 |
| Est. Completion | 2029-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07013591
The ClinicalTrials.gov registry entry for NCT07013591 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07013591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07013591 about?
NCT07013591 is a clinical study titled "Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery". The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentra...
What is the current status of trial NCT07013591?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-06-10. Estimated completion is 2029-01-01.
What interventions are being tested in trial NCT07013591?
The interventions under investigation include: Placebo (OTHER), MIB-626 (DRUG).
Who is sponsoring clinical trial NCT07013591?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.